Medifast Reaches Cooperation Agreement with Activist Investor Steamboat Capital, Adds Two Directors

summarizeSummary

Medifast has entered into a cooperation agreement with activist investor Steamboat Capital, which holds a significant stake, leading to the appointment of two Steamboat designees to the Board and the departure of two existing directors.

check_boxKey Events

• Cooperation Agreement Signed

  Medifast entered into a Cooperation Agreement with activist investor Steamboat Capital Partners on March 19, 2026.

• Activist Board Representation

  Two Steamboat Capital designees, Parsa Kiai and Jeffrey Rose, will be nominated for election to Medifast's Board of Directors at the 2026 Annual Meeting.

• Director Departures

  Existing directors Jeffrey Brown and Michael Hoer will not stand for re-election, making way for the new appointments.

• Significant Activist Stake

  Steamboat Capital beneficially owns approximately 5.98% of Medifast's outstanding shares.

auto_awesomeAnalysis

This agreement signals increased shareholder oversight and potential strategic shifts for Medifast, which recently reported a substantial revenue decline and net loss. The activist investor's representation on the board, coupled with a standstill agreement, suggests a collaborative effort to improve financial performance and unlock shareholder value. Investors will be watching for how these new board members influence the company's strategy, particularly in light of competitive pressures from GLP-1 weight loss medications.